Tildrakizumab is a Monoclonal Antibody owned by Sun Pharma Advanced Research Company, and is involved in 17 clinical trials, of which 11 were completed, and 6 are ongoing.

Tildrakizumab is an anti-interleukin (IL)-23A antibody. It works by selectively targeting IL-23, specifically the p19 component of the cytokine. IL-23 is a naturally occurring cytokine that are involved in inflammatory and immune responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation. IL-23 has a role in chronic inflammation, which is a common characteristic of many autoimmune diseases. IL-23 promotes the Th17 pathway, which is active in the pathogenesis of inflammatory diseases, including psoriasis.

The revenue for Tildrakizumab is expected to reach a total of $5.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Tildrakizumab NPV Report.

Tildrakizumab was originated by Schering-Plough and is currently owned by Sun Pharma Advanced Research Company. Sun Pharmaceutical Industries and Almirall are the other companies associated in development or marketing of Tildrakizumab.

Tildrakizumab Overview

Tildrakizumab (Ilumya, Ilumetri) is a monoclonal antibody, acts as an immunosuppressant agent. It is formulated as solution for subcutaneous route of administration. Tildrakizumab is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Tildrakizumab is under development for the treatment of psoriatic arthritis and plaque psoriasis. It was also under development for ankylosing spondylitis and axial spondyloarthritis.

Almirall Overview

Almirall is a specialty pharmaceutical company that researches, develops, manufactures, and commercializes proprietary medicines and licensed products. The company’s major area of focus is dermatology covering psoriasis, eczema, acne, and other skin infections. It also develops products for autoimmune diseases including rheumatoid arthritis and multiple sclerosis; and gastrointestinal diseases including irritable bowel syndrome with constipation. The company also works together with small and medium-sized companies and healthcare professionals to develop medical solutions and provide them to patients. It operates through affiliates in Europe and Central America and has R&D centers in Spain and Germany. Almirall is headquartered in Barcelona, Spain.

The company reported revenues of (Euro) EUR827.2 million for the fiscal year ended December 2021 (FY2021), an increase of 2.4% over FY2020. In FY2021, the company’s operating margin was 0.7%, compared to an operating margin of 11.4% in FY2020. The net loss of the company was EUR40.9 million in FY2021, compared to a net profit of EUR74.3 million in FY2020. The company reported revenues of EUR197.2 million for the third quarter ended September 2022, a decrease of 54.8% over the previous quarter.

Quick View – Tildrakizumab

Report Segments
  • Innovator (NME)
Drug Name
  • Tildrakizumab
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Immunology
  • Musculoskeletal Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.